MARKET

CERO

CERO

CERo Therapeutics
NASDAQ
1.020
+0.060
+6.23%
After Hours: 0.9800 -0.04 -3.92% 19:55 03/14 EDT
OPEN
0.9500
PREV CLOSE
0.9602
HIGH
1.030
LOW
0.9420
VOLUME
258.56K
TURNOVER
--
52 WEEK HIGH
376.00
52 WEEK LOW
0.9315
MARKET CAP
3.09M
P/E (TTM)
-0.0270
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 1d ago
CERo Therapeutics Presents Preclinical Data Demonstrating CER-1236 May Be Targeted To Ovarian Cancer Cells Without Toxicities At 2025 SITC Spring Scientific Cellular Therapy For Solid Tumors Meeting
Benzinga · 1d ago
Weekly Report: what happened at CERO last week (0303-0307)?
Weekly Report · 4d ago
Cero Therapeutics announces progress in initiation of Phase 1 trial
TipRanks · 03/06 13:21
CERO THERAPEUTICS HOLDINGS, INC. ANNOUNCES PROGRESS IN INITIATION OF PHASE 1 CLINICAL TRIAL BY EXECUTING AN AGREEMENT WITH CONTRACT RESEARCH ORGANIZATION CELLCARTA TO MANAGE TRANSLATIONAL ASSAYS
Reuters · 03/06 13:15
CERo Therapeutics to Present Preclinical Data on CER-1236 for Ovarian Cancer at SITC Conference
NASDAQ · 03/05 13:20
CERo Therapeutics Holdings To Present Data At The Society For Immunotherapy Of Cancer Spring Scientific March 12-14, 2025
Benzinga · 03/05 13:16
Weekly Report: what happened at CERO last week (0224-0228)?
Weekly Report · 03/03 09:37
More
About CERO
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Webull offers CERo Therapeutics Holdings Inc stock information, including NASDAQ: CERO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CERO stock methods without spending real money on the virtual paper trading platform.